Vapotherm today set the pricing range on an initial public offering that would fetch $60 million at the midpoint.
Exeter, N.H.-based Vapotherm developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said.
Today Vapotherm said it plans to issue 4 million shares priced at $14 to $16 apiece, for gross proceeds of $56.0 million to $64 million.
Vapotherm has said the proceeds from the $57.5 million offering are earmarked for expanding its sales and marketing teams and increase its marketing footprint in the U.S. and overseas. Some of the cash will also go toward R&D, working capital and general expenses, according to a regulatory filing.
The company plans to list on the New York Stock Exchange under the “VAPO” symbol.
The company posted losses of -$31.0 million, or -$3.20 per share, on sales of $35.6 million last year, widening its losses by 34.4% on sales growth of 18.2% compared with 2016. For the nine months ended Sept. 30, Vapotherm reported losses of -$29.6 million, or -$2.54 per share, on sales of $30.7 million, increasing its losses by 34.7% on sales growth of 21.8% compared with the first three quarters of 2017, according to the filing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.